Karyopharm Therapeutics (KPTI) is scheduled to report Q1 earnings on May 11, 2026. Analysts estimate EPS of $-1.33 and quarterly revenue of $34.10M.

In the most recent quarter (Q4), Karyopharm Therapeutics reported EPS of $-2.23, missing estimates of $-2.10 by 0.06%. Revenue came in at $34.08M, exceeding the estimate of $33.16M by 0.03%.

Karyopharm Therapeutics has missed EPS estimates in 3 consecutive quarters.

Over the last 4 quarters, Karyopharm Therapeutics has averaged an EPS surprise of 0.11% and a revenue surprise of 0.06%.